Navigation Links
Boca Pharmacal Receives FDA Approval on Glycopyrrolate Tablets
Date:10/21/2011

CORAL SPRINGS, Fla., Oct. 21, 2011 /PRNewswire/ -- Boca Pharmacal, Inc., today announced that it has received approval from the FDA of its Abbreviated New Drug Application (ANDA) for Glycopyrrolate Tablets USP, 1 mg and 2 mg, the generic version of Robinul Tablets, 1 mg and Robinul Forte Tablets, 2 mg, distributed by Shionogi Pharma, Inc. Glycopyrrolate tablets are intended for use as adjunctive therapy in the treatment of peptic ulcers.

"We're up to our third approval this year," said Robert Edwards, CEO of Boca Pharmacal.  "Each approval – including Glycopyrrolate Tablets – has been consistent with our mission to pursue and provide products to the marketplace that are important to our customers, but may be overlooked by some of the huge multinationals. We're continuing to file new ANDAs, and will keep doing so in our ongoing effort to provide the generic products our customers – and their patients – need."

Boca Pharmacal, Inc.

Since its beginnings in 1998, Boca Pharmacal's mission has been to offer niche items that were overlooked by some of the larger generic companies as affordable alternatives to brand-named products.

Using multiple facilities across the globe, Boca Pharmacal has a broad reach and a reliable vertical structure that allows them to develop products that include tablets and capsules, semi-solids, solutions, and suspensions. They continue to invest in research and development to make sure they're providing their clients with a wide variety of offerings. The Boca Pharmacal product line is marketed to chains, wholesalers, distributors, managed markets and government agencies.  Boca Pharmacal is located at 3550 NW 126th Avenue, Coral Springs, Florida, 33065. For more information visit www.bocapharmacal.com.CONTACT:

Jennifer MouraBoca Pharmacal3550 NW 126th AveCoral Springs, FL 33065Phone: (954) 346-8810Email: info@bocapharmacal.com
'/>"/>

SOURCE Boca Pharmacal, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Mission Pharmacal Launches CitraNatal(R) Assure Prescription Prenatal Vitamin
2. Mission Pharmacal Launches New Vitamin B6-Rich Prescription Prenatal Vitamin, CitraNatal(R) B-Calm
3. Nautilus Neurosciences and Mission Pharmacal Announce Exclusive Co-Promotion Agreement for CAMBIA™ (diclofenac potassium for oral solution) for the Acute Treatment of Migraine to the Womens Health Market
4. Boca Pharmacal Receives FDA Approval for Hydrocodone Bitartrate and Acetaminophen Tablets
5. Reclast(R) Receives US FDA Approval as First and Only Once-Yearly Treatment for Women With Postmenopausal Osteoporosis
6. Indevus Receives Approvable Letter From FDA for VALSTAR(R) for Bladder Cancer Therapy
7. Auxilium Pharmaceuticals, Inc. Receives Clearance to Resume Clinical Trials for XIAFLEX(TM)
8. Abbott Receives Supplemental FDA Approval for its Best-in-Class in Sensitivity RealTime HIV-1 Viral Load Test
9. GlaxoSmithKline Receives New HHS Order for H5N1 Bulk Antigen. First North American Clinical Trials with GSKs Candidate Pre-pandemic Flu Vaccine to Start.
10. CryoCor Receives FDA Approval for Right Atrial Flutter
11. Ranbaxy Receives Approval to Manufacture and Market Hydrocodone Bitartrate and Acetaminophen Tablets USP
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/25/2016)... , May 25, 2016 ... the precision of circulating tumour DNA (ctDNA) analysis ... the appointment of Professor Clive Morris ... leadership across the clinical development programme, scientific collaborations, ... help deliver significant improvements in clinical outcomes for ...
(Date:5/24/2016)... , May 24, 2016 ... Markt gebracht, die es Ärzten erlaubt, ihre Expertise ... behandeln: MDLinking kombiniert Live Streaming mit einer Instant-Messaging-Funktion ... zu kommunizieren. Mediziner in Europa, Afrika, Asien und ... bereits für die Plattform registriert. Information ...
(Date:5/24/2016)... , May 24, 2016 ... beide primären Endpunkte und demonstriert ... in ‚ausgezeichneter plus guter , ...    ,      (Logo: http://photos.prnewswire.com/prnh/20130829/633895-a ... heute neue positive Daten von der MORA-Studie der ...
Breaking Medicine Technology:
(Date:5/25/2016)... , ... May 25, 2016 , ... Stern Environmental ... will be selling the device branded as Stern’s Real Time Monitoring (RTM) ... bedbugs to the hotel and motel industry, colleges for use in dormitories, shelters, and ...
(Date:5/24/2016)... ... 24, 2016 , ... According to an article published May 11th ... to reduce the amount of calories they consumed by 25% experienced some interesting health ... better sleep, improved quality of life, and enhanced sexual function compared to the other ...
(Date:5/24/2016)... (PRWEB) , ... May 24, 2016 , ... ... announces its inaugural health care blockchain event, Distributed: Health, to be held in ... Nashville’s downtown Symphony Center. , A 24-hour Hackathon preceding the event will host ...
(Date:5/24/2016)... ... May 24, 2016 , ... To better understand the impact of ... to examine gender differences in lung cancer. Today, the Lung Association announced Sharad Goyal, ... in Women Award, funded by the American Lung Association’s LUNG FORCE initiative, which raises ...
(Date:5/24/2016)... Clarkston Michigan (PRWEB) , ... May 24, 2016 ... ... Certified Nurse Midwife, Roberta Jordan. , Roberta Jordan is a Certified Nurse ... from Grand Valley State University and then went on to complete her masters ...
Breaking Medicine News(10 mins):